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Ergotamine-Induced Upper Extremity
Ischemia: A Case Report
Ergotamine-induced limb ischemia is an extremely rare case. We present a
case of a 64-year-old man, who developed ischemia on the right upper extremity
due to long-term use of Ergot for migraine headache. Angiography revealed dif-
fused, smooth, and tapered narrowing of the brachial artery. The patient was suc-
cessfully treated with intravenous nitroprusside. 
rgot alkaloids are widely used for the relief from migraine headache (1).
Ergotamine can cause serious peripheral vascular ischemia and results in
amputation (2 6). As Ergotamine-induced ischemia is a very rare case,
the radiologists are not entirely familiar with its characteristic features. However, the
clinical importance lies in the fact that, delayed diagnosis leads to serious irreversible
complications. In the present study, a review of literature on presentation, diagnosis
and treatment of the complications induced by Ergotamine has been reported. 
CASE REPORT
A 64-year-old man with a 15-year long history of hypertension was presented to the
emergency room with a 24-hour history with symptoms of cyanosis and pain on the
right upper extremity, consistent with acute ischemia. The major physical findings
revealed that the right upper extremity was pale, cold, and exhibited reduced
sensation and power. Radial pulses were observed to be absent.
Blood pressure was 130/80 mmHg and heart rate was regular at 64 beats per
minute. Laboratory values indicated an increase in white blood cell count of 11,400
/uL, normal hemoglobin value of 15.5 g/dL and elevated creatininc kinasl MB (CK-
MB) value of 33.2 ng/mL (normal, 0 5 ng/mL). The increased levels of BUN (31.9
mg/dL) (Blood Urea Nitrogen) and serum creatinine (1.8 mg/dL) returned back to
baseline value within three days. Levels of Aspartate aminotransferase (range, 68
266 IU/L) and alanine aminotransferase (range, 28 79) were increased.
A right transfemoral approach was performed with placement of a 6-F sheath. 
A 5-F angiographic catheter (H1; Cook, Bloomington, IN) was advanced into the
right axillary artery. Angiogram obtained after injection of contrast medium in right
axillary artery revealed a smooth, tapered narrowing of the brachial artery without
opacification of radial and ulnar artery (Figs. 1A, B). At the time of angiography,
passing of guide wire across the narrowing and occlusive segment was attempted, but
these efforts were unsuccessful. The diagnosis of unusual pattern of Raynaud’s disease
was initially made, eventually incorrect.
A fear of gangrenous changes in right upper extremity, he had undergone intra-
arterial papaverine injection of 30 mg and a right axillary-radial bypass surgery.
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EOver a period of approximately two hours, there was a
dramatic improvement in the color of the patient’s upper
extremity and radial pulses became palpable, but cyanosis
and pain persisted at phalangeal area. 
In addition to intravenous infusion of prostaglandin E1
and heparin, two days later, the patient underwent ipsilat-
eral sympathectomy with the subsequent disappearance of
cyanosis and pain on phalangeal area. There was improve-
ment in motor disability, though there was no complete
recovery. Follow up angiography was performed to
evaluate the patency of graft seven days later. 
Arteriography examination demonstrated normal arterial
anatomy of the right arm as well as the patent graft (Figs.
1C E). The patient’s postoperative recovery was unevent-
ful, and he was discharged in a good condition.
Anticoagulation and antiplatelet regimens were prescribed
at the time of discharging. Eight days later, the patient
returned for the same ischemic symptoms of the right
upper extremity. Repeated angiography revealed the
similar findings which had been demonstrated during first
angiography and also occlusion of graft was noticed. The
diagnosis of ergotamine-induced vasospasm was made only
after that and treatment was initiated by discontinuing the
intake of offending drug and an intravenous infusion of
nitroprusside was initiated at a rate of 4  g/kg/minute. 
The drug infusion was continued over four days until
there was relief from pain and cyanosis. We noticed that
for over a period of 10 years the patient had been
prescribed Ergotamine for the treatment of migraine.
DISCUSSION
Ergotamine is an alkaloid produced by a fungus,
Clariceps purpura. Epidemics would sometimes occur
when food stuffs become contaminated with Clariceps
purpura. People who consumed the fungus contaminated
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Fig. 1. Right upper extremity
arteriograms in a 64-year-old
man with pain and 
cyanosis on right forearm. 
A, B. Diffuse, smooth tapered
narrowing of the right brachial
artery (arrows) is demonstrated
without opacification of radial and
ulnar artery.
C-E. Follow up arteriogram
demonstrates normal arterial
anatomy of upper extremity as
well as patent graft (arrows).
DEgrain suffered from limb ischemia and discoloration of
extremities. 
Most of the cases of Ergotamine toxicity are due to
medication ingestion, either acutely or chronically (2).
Ergotamine has been widely used for the treatment and
prevention of migraine headaches. This particular alkaloid
can cause intense peripheral vasoconstriction which can
lead to gangrene and amputation. Ergotamine-induced
vascular ischemia is rare, but potentially serious complica-
tion may be induced through two mechanisms: vasospasm
and thrombus formation. The latter may be caused by
stasis and a postulated direct endothelial damage may be
caused by Ergotamine. Toxicity can occur from chronic use
of therapeutic doses, acute ingestion of excessive amounts,
and acute ingestion of normal doses in hypersensitive
patients. A number of conditions are known to potentiate
the vasospastic effects of Ergotamine like, fever, sepsis,
malnutrition, thyrotoxicosis, pregnancy, liver and renal
insufficiency, coronary artery disease, and peripheral
vascular disease (3). The triggering factor for the develop-
ment of Ergotamine toxicity in the present case is still
uncertain, but a possible reason could be hepatitis
(elevated liver enzyme) with transient renal dysfunction.
Drugs may also be responsible for an increase in the side
effects of Ergotamine (4, 5): oral contraceptives, xanthine
derivatives, antiviral agents, antibiotics interfering with the
liver metabolism of Ergotamine (i.e. clarithromycin,
ampicillin, erythromycin, and troleandomycin). 
Recently, Baldwin et al. described a case of Ergotamine
toxicity in an human immunodeficiency virus infected
patient treated with antiviral protease inhibitor (6).
Ischemia caused by Ergotamine intoxication affects the
lower extremities more commonly than the upper extremi-
ties. The external carotid arteries are often involved with a
rare involvement of coronary, mesenteric, renal, and retinal
arteries. The diagnosis of this rare condition requires a high
index of suspicion in patients with migraine and a careful
inquiry about their medication history. The angiographic
findings of the affected vessels reveal thin, threadlike and
smooth tapered narrowing of the arteries with or without
collateral formation (7). Thrombus results from stasis distal
to arterial spasm with either bilateral or symmetrical
involvement, and the areas of stenosis may be diffused or
localized. Many therapeutic modalities can be used to
reverse the vasoconstriction (8, 9). The first step of the
treatment is discontinuation from the offending drug. 
When vascular thrombosis is suspected, heparin, a low
molecular weight dextran and streptokinase has been
suggested to reduce tissue loss. A number of pharmaco-
logic agents have also been used to treat the vasospasm.
Nitroprusside, a direct acting vasodilator, is effective but
can be used only for shorter periods of time and prompt
recurrence of symptoms have been reported after discon-
tinuation. Tolazoline, calcium channel blockers and
prostaglandin E1 are able to produce vasodilatation.
Nifedipine is the most potent peripheral vasodilator of the
group and has been successfully used to treat Ergotamine
toxicity. In severe forms of ischemia refractory to pharma-
cologic treatment, surgical sympathectomy or intraarterial
balloon dilatation can be effective (10), and the manage-
ment depends on early diagnosis of the symptoms. 
In our case, Ergotamine-induced ischemia was not
suspected during first angiography. Uninterrupted medica-
tion for migraine is thought to play a significant role in the
development of recurrent symptoms.
The present case emphasizes the importance of acquiring
a detailed medication history. Combination of heparin,
prostaglandin E1, and sympathectomy did not prevent the
progression of cyanosis in our case, but intravenous
injections of nitroprusside could relieve the symptoms. An
understanding of the clinical features and angiographic
findings of Ergotamine-induced ischemia is essential in
early diagnosis and treatment to prevent irreversible
complications.
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